RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase not stated

Registered title, quoted from ClinicalTrials.gov

Clinical Study of 18F-Labeled FAPI-04 in PET Imaging of Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Affiliated Hospital of Qingdao University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06916338, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. ECOG score 0-2 and expected survival ≥ 12 weeks;

    Inclusion criterion 4

  3. Presence of at least 1 measurable lesion (RECIST 1.1 criteria);

    Inclusion criterion 3

  4. Pregnant/nursing female or not using effective contraception;

    Exclusion criterion 4

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06916338, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age 18-75 years old, any gender;
  • Clinically or pathologically confirmed diagnosis of breast cancer, or suspected recurrence/metastasis;
  • Presence of at least 1 measurable lesion (RECIST 1.1 criteria);
  • ECOG score 0-2 and expected survival ≥ 12 weeks;
  • Laboratory markers are met:

Blood count: WBC ≥4.0×10⁹/L, PLT ≥100×10⁹/L, Hb ≥90 g/L Liver and kidney function: ALT/AST ≤ 2.5 × ULN, SCr ≤ 1.5 × ULN;

  • Signed informed consent.

Exclusion Criteria:

  • Major surgery or trauma within 4 weeks;
  • Severe infection, liver or kidney insufficiency;
  • History of allergies (developer components);
  • Pregnant/nursing female or not using effective contraception;
  • Inability to co-operate with PET (e.g. claustrophobia);
  • Any other situation that researchers considered it unsuitable to participate in the trial.

Quoted from ClinicalTrials.gov, NCT06916338, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06916338, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06916338